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Although great advances have recently been made in the study of signal transduction, the pathogenesis
of affective disorders is still unknown. There is mounting evidence suggesting that elevated phosphoi-
nositideeprotein kinase C (PIePKC) signal transduction pathway may be a pathophysiological feature of
bipolar and major depressive disorders. The aim of the present study was to further investigated the
phospholipase Ceprotein kinase C (PLCePKC) cascade by evaluating the effect produced by an acute
blockade of this intracellular pathway at PLC and PKC level. Adult male mice were administered with
pharmacological inhibitors of PLC or PKC and then subjected to the forced swim test (FST), an animal
model which emulates the behavioural despair paradigm of depression. In this study we also tested the
hypothesis that it might be possible to selectively modulate depressive behaviour by inhibiting the
expression of specific PLC and PKC isoforms by means of specific antisense oligonucleotides (aODNs).
Administration of the PLC inhibitors neomycin and U73122 as well as of the PKC inhibitors calphostin
C and chelerytrine dose-dependently reduced the immobility time in the FST producing an antide-
pressant-like behaviour. Selective knockdown of the PLCb1 and PKCg isoforms also induced an antide-
pressant phenotype. Conversely, the inhibition of the expression of PLCb3 was unable to modify the
immobility time values. The PLC and PKC modulators used, at the highest effective doses, altered neither
locomotor activity nor motor coordination. We demonstrate that selective blockade of PLCb1ePKCg
signalling pathway produces an antidepressant-like phenotype in mice.
 2011 Elsevier Ltd. All rights reserved.1. Introduction
Research into the pathophysiology of affective disorders and the
mechanism of action of antidepressant drugs has primarily focused
on altered monoamine neurotransmission. However, extensive
studies have failed to prove conclusively abnormalities in neuro-
transmitter or post-synaptic receptor function. This has led to an
examination of post-receptor signal transduction systems
(Marazziti et al., 2009).
There is mounting evidence suggesting that an alteration of
the phosphoinositideeprotein kinase C (PIePKC) signal trans-
duction pathway may be associated to affective disorders. In the
PI-signalling system, agonists’ stimulation of G protein coupled
receptors causes hydrolysis of the substrate, phosphatidyl inositolFST, Forced swim test; i.c.v.,
rotein kinase C; PLC, Phos-
ology, Viale G. Pieraccini 6,
39 055 4271280.
otti).
All rights reserved.4,5-bisphosphate (PIP2), by the enzyme phospholipase C (PLC),
resulting in the formation of two second messengers, inositol
1,4,5-trisphosphate (IP3) and diacylglycerol (DAG) (Berridge and
Irvine, 1989). IP3 stimulates the release of intracellular calcium
from the endoplasmic reticulum, and DAG stimulates the enzyme
protein kinase C (PKC) (Nishizuka, 1992).
Platelets from patients with bipolar disorders (Brown et al.,
1993; Soares et al., 2001) or major depressive disorders (Dwivedi
et al., 1998; Karege et al., 1996) exhibit several indices consistent
with an increased PI activity, implying that depression is associated
with over-stimulation of the PI pathway in platelets. More direct
evidence of an increased PI-related signal transduction in affective
disorders comes from studies in post-mortem human brain tissues
(Friedman and Wang, 1996). In particular, these alterations might
be a consequence of increased PI levels (Silverstone et al., 2005) or
Gaq/11 and PLC immunoreactivity (Mathews et al., 1997). An
elevated PKC signalling activity has also been reported in platelets
(Wang et al., 1999; Pandey et al., 1998) and brain samples (Wang
and Friedman, 1996) from depressed patients. A further confirma-
tion of this hypothesis is given by the observation that antide-
pressant drugs from different classes down-regulate the PIePKC
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et al., 2002), desensitising Gaq-coupled receptor-generated PLC-
mediated hydrolysis of PIP2 (Dyck and Boulton, 1989; Pandey et al.,
1991) or decreasing PKC activity (Mann et al., 1995; Morishita and
Watanabe, 1997) in animal and human studies.
On this matter, there is not a general consensus. In contrast to
the hypothesis of an over-stimulated PI cascade, it has been sug-
gested that a hypofunctionality, rather than a hyperactivity, of the
PIePKC pathway might be related to affective disorders. Studies
performed in platelets and human brain samples reported no
difference (Coull et al., 2000) or decreases in indices of PI or PKC
signalling (Jope et al., 1996; Pandey et al., 2002) in patients suffering
frombipolar ormajor depressive disorders. Specifically, a decreased
activity and expression of PLC and PKC have been observed in
teenage suicide victims (Pandey et al., 1999, 2004).
As a step towards better understanding of the involvement of
PIePKC signalling pathway in mood disorders, we further investi-
gated the PLCePKC cascade by evaluating the effect produced by
a pharmacological blockade of this intracellular pathway in mice
exposed to the forced swim test, an animal model which emulates
the behavioural despair paradigm of depression. In this study we
also tested the hypothesis that it might be possible to selectively
modulate depressive behaviour in antidepressant-responsive
behavioural paradigms by inhibiting the expression of specific PLC
and PKC isoforms by using an antisense strategy.
2. Materials and methods
2.1. Animals
Male Swiss albino mice (20e22 g) from the Morini (San Polo d’Enza, Italy)
breeding farm were used. Ten mice were housed per cage (26  41 cm). The cages
were placed in the experimental room 24 h before the test for acclimatization. The
animals were fed a standard laboratory diet and tap water ad libitum and kept at
23 1 C with a 12 h light/dark cycle, light on at 7 a.m. All experiments were carried
out in accordance with the European Communities Council Directive of 24
November 1986 (86/609/EEC). All efforts were made to minimise animal suffering,
and to reduce the number of animals used.
2.2. Intracerebroventricular injection technique
Intracerebroventricular (i.c.v.) administration was performed under ether
anaesthesia, as previously described (Galeotti et al., 2003). Briefly, during anaes-
thesia, mice were grasped firmly by the loose skin behind the head. A 0.4 mm
external diameter, hypodermic needle attached to a 10 ml syringe was inserted
perpendicularly through the skull and no more than 2 mm into the brain of the
mouse, where 5 ml were then administered. The injection site was 1 mm to the right
or left from the mid-point on a line drawn through to the anterior base of the ears.
Injections were performed into the right or left ventricle randomly. To ascertain that
the drugs were administered exactly into the cerebral ventricle, some mice (20%)
were injected with 5 ml of diluted 1:10 India ink and their brains examined
macroscopically after sectioning. The accuracy of the injection technique was
evaluated and the percentage of correct injections was determined to be 95%. Drug
concentrations were prepared so that the necessary dose could be administered in
a volume of 5 ml per mouse.
2.3. Forced swim test
The forced swimming test used was the same as described by Porsolt et al.
(1977). Briefly, mice were placed individually into glass cylinders (height: 25 cm,
diameter: 10 cm) containing 6 cm of water maintained at 22e23 C and left there for
6 min. A mouse was judged to be immobile when it floated in the water, in an
upright position, and made only small movements to keep its head above water.
The duration of immobility was recorded during the last 4 min of the 6-min test.
A decrease in the duration of immobility is indicative of an antidepressant-like
effect. 12e15 mice per group were tested.
2.4. Motor coordination
The motor coordination was assessed by using the rota rod test. The apparatus
consisted of a base platform and a rotating rod with a diameter of 3 cm and a non-
slippery surface. The rod was placed at a height of 15 cm from the base. The rod,
30 cm in length, was divided into 5 equal sections by 6 disks. Thus, up to 5mice weretested simultaneously on the apparatus, with a rod-rotating speed of 16 r.p.m. The
integrity of motor coordinationwas assessed on the basis of the number of falls from
the rod in 30 s. Those mice scoring less than 3 and more than 6 falls in the pretest
were rejected (20%). The number of falls was measured before (pretest) and 15, 30
and 45 min after the beginning of the test. 10 mice per group were used.
2.5. Locomotor activity
The locomotor activity was evaluated by using the holeeboard test. The appa-
ratus consisted of a 40 cm square plane with 16 flush mounted cylindrical holes
(3 cm diameter) distributed 4 by 4 in an equidistant, grid-like manner. Mice were
placed on the centre of the board one by one and allowed to move about freely for
a period of 10 min each. Two photobeams, crossing the plane from mid-point to
mid-point of opposite sides, thus dividing the plane into 4 equal quadrants, auto-
matically signalled the movement of the animal (counts in 5 min) on the surface of
the plane (locomotor activity). Miniature photoelectric cells, in each of the 16 holes,
recorded (counts in 5 min) the exploration of the holes (exploratory activity) by the
mice. 12e15 mice per group were tested.
2.6. Antisense oligonucleotides
Phosphodiester oligonucleotides (ODNs) protected by terminal phosphor-
othioate double substitution (capped ODNs) against possible exonuclease-mediated
degradationwere obtained from Tib Molbiol (Genoa, Italy). The following aODNwas
produced against PLCb3: 50-T*G G*TGGTCATCTGGGATG*T*A-30 where* indicates
the phosphorothioate residue. Anti-PLCb3 ODN was designed from the sequence
2649e2669 of the gi: 31982121 NCBI SequenceWiewer; this sequence was searched
through GenBank and found to be unique to its respective PLCb3 isoenzyme and
was based on mouse sequence. The aODN against PKCg was the following:
50-A*C*GAAGTCCGGGTTCACA *T*A-30 . Anti-PKCg ODN was designed from the
sequence 2359e2378 of the gi: 31982442 NCBI Sequence Wiewer; this sequence
was searched through GenBank and found to be unique to its respective PKCg
isoenzyme and was based on mouse sequence. The aODN against PLCb1 was the
following: 50- G*C*T GTC GGA CAC G*C*A -30 , corresponding to nucleotides 49e63
of the PLCb1 gene sequence. Anti-PLCb3 was previously characterised by in vitro and
in vivo experiments in our laboratory (Galeotti et al., 2006). Anti-PLCb1 was previ-
ously characterised by Sanchez-Blazquez and Garzon (1998) and by us. We
confirmed the aODN effect on PLCb1 protein levels by performing immunoblotting
experiments. We observed a statistically significant reduction of the expression of
PLCb1 (45.1  6.9) after aODN treatment in comparison with mice treated with
dODN. The 15 and 20mer fully degenerated ODNs (dODNs), where each base was
randomly G, or C, or A, or T, were used as control ODN treatment. Antisense ODNs
and dODNs were pre-incubated at 37 C for 30 min with an artificial cationic lipid
(13 mM DOTAP, Sigma, Milan, Italy) and i.c.v. injected to mice in a 5 ml final volume.
Mice received a single i.c.v. injection on day 1, 2 and 3. Behavioural and western
blotting experiments were performed on day 4, 24 h after the last i.c.v. injection.
2.7. Preparation of membranes
Brain areas to conduct western blotting experiments were collected 24 h after
the end of the anti-PKCg i.c.v treatment. Mouse brains were dissected to separate
specific areas. Mouse hippocampus and frontal cortex were homogenised in
a homogenisation buffer containing 25 mM TriseHCl pH ¼ 7.5, 25 mM NaCl, 5 mM
EGTA, 2.5 mM EDTA, 2 mM NaPP, 4 mM PNFF, 1 mM Na3VO4, 1 mM PMSF, 20 mg/ml
leupeptin, 50 mg/ml aprotinin, 0.1% SDS. The homogenate was centrifuged at
9000  g for 15 min at 4 C, the low speed pellet was discarded and the supernatant
was stored at80 C. Protein concentrationwas quantified using Bradford’s method
(protein assay kit, Bio-Rad Laboratories, Milan, Italy).
2.8. Western blot analysis
Membrane homogenates (10 mg) made from hippocampus and frontal cortex
regions of dODN and aODN treated mice were separated on 10% SDSePAGE and
transferred onto nitrocellulose membranes (110 min at 120 V) using standard
procedures. Membrane were blocked in PBST (PBS containing 0.1% Tween) con-
taining 5% nonfat dry milk for 120 min. Following washings, blots were incubated
overnight at 4 C with specific antibodies against PKCg (1:1000; Santa Cruz
Biotechnology Inc, CA, USA) or b-actin (1:1000 dilution). After being washed with
PBS containing 0.1% Tween, the nitrocellulose membrane was incubated with goat
anti-rabbit horseradish peroxidase-conjugated secondary antisera (1:10,000) and
left for 1 h at room temperature. Blots were then extensively washed according to
the manufacturer’s instruction and developed using enhanced chemiluminescence
detection system (Pierce, Milan, Italy). Exposition and developing time used was
standardised for all the blots. Densitometric analysis of scanned images was per-
formed on aMacintosh iMac computer using the public domain NIH Image program.
Measurements in control samples were assigned a relative value of 100%.
Measurements were normalised relative to b-actin, used as loading control.
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Fig. 1. Antidepressant-like effect produced by blockade of the PLC activity. Dose-
dependent decrease of the immobility time in the mouse forced swimming test by the
pharmacological PLC blockers U73122 (0.5e5 mg per mouse i.c.v.) (a) and neomycin
(1e20 mg per mouse i.c.v.) (b). Effect produced by knockdown of PLCb1 and PLCb3 (c).
Amitriptyline (AMI, 10 mg kg1 i.p.) was used as reference drug. VEH: 0.5% DMSO; SAL:
saline; dODN: degenerate ODN. Vertical lines represent SEM. *p < 0.05, **p < 0.01,
***p < 0.001 in comparison with control mice.
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The following drugswere used: calphostin C, chelerytrine, neomycin, U73122 (1-
[6-((17b-3-methoxyestra-4,3,5(10)-trien-17-yl)amino)hexyl]1H-pyrrole-2,5-dione),
U73343 (1-[6-[[17b-3-methoxyestra-1,3,5(10)-trien-17-yl]amino]hexyl]-1H-pyrro-
lidinedione), PMA (phorbol-12-myristate-13-acetate), PDBu (phorbol-12,13-dibu-
tyrate) (Calbiochem, Milan Italy); D-amphetamine hydrochloride (De Angeli, Rome,
Italy); amitriptyline (Sigma, Milan, Italy). D-amphetamine, amitriptyline and
neomycin were dissolved in isotonic (NaCl 0.9%) saline solution, U73122, U73343,
calphostin C, chelerytrine, PMA, PDBu in 0.5% DMSO. Drug concentrations were
prepared so that the necessary dose could be administered in a volume of 5 ml per
mouse by intracerebroventricular (i.c.v.) injection and 10 ml kg1 by subcutaneous
(s.c.) or intraperitoneal (i.p.) injection. PMA, PDBu, chlerytrine and Calphostin C
where injected i.c.v. 1 h before the test; U73122, neomycin and D-amphetamine
(2 mg kg1 s.c.) were injected 10 min before behavioural tests, amitriptyline
(10 mg kg1 i.p.) was injected 30 min before the tests. Doses and administration
schedules were chosen on the basis of time-course and dose-response curves per-
formed in our laboratory (Galeotti et al., 2003). Furthermore, literature data confirm
the selectivity and efficacy of the above-mentioned treatments at time and
concentration used.
2.10. Statistical analysis
All experimental results are given as the mean  s.e.mean. Analysis of variance
(one-way ANOVA) followed by Bonferroni/Dunn post hoc testwas used for statistical
analysis.
3. Results
3.1. Antidepressant-like effect induced by inhibition of
phospholipase C (PLC)
The effect produced by blockade of the PLC in a behavioural
despair paradigm was determined in the mouse forced swimming
test (FST). A reduction of the immobility was produced by the PLC
blocker U73122 (F(7,93) 4.750 p < 0.001). A statistically significant
effect was reached at the doses of 5 mg (p < 0.05) per mouse i.c.v.
(Fig. 1a). Treatment with U73343, analogue of U73122 ineffective
on PLC, at the dose of 5 mg per mouse i.c.v. was devoid of any effect
(Fig. 1a). The i.c.v. administration of the PLC inhibitor neomycin
dose-dependently reduced the immobility time (F(5,78) 5.940
p < 0.0001). Bonferroni/Dunn multiple comparison analysis
showed that the administration of 10 (p < 0.05) or 20 mg (p < 0.01)
per mouse i.c.v. produced a statistically significant antidepressant-
like effect (Fig. 1b).
The reduction of the expression of the PLCb1 isoform by aODN
pretreatment induced an antidepressant-like phenotype (F(3,48)
3.937 p < 0.001). The dose of anti-PLCb1 of 1 nmol per mouse i.c.v
was ineffective whereas the dose of 3 nmol per mouse reached the
statistical significance (p < 0.05; Fig. 1c). Conversely, the knock-
down of the PLCb3 isoform did not modify the immobility time
values in comparison with the dODN-treated group (F(1,23) 1.717
p ¼ 0.227) (Fig. 1c).
In the same experimental conditions, amitriptyline
(10 mg kg1 s.c.), used as reference drug, produced an antide-
pressant-like effect.
3.2. Antidepressant-like effect induced by inhibition of protein
kinase C (PKC)
The i.c.v. administration of calphostin C, a PKC blocker,
decreased the immobility time values in the mouse FST. Calphostin
C, at 0.001 mg per mouse i.c.v., was devoid of any effect, whereas the
doses of 0.01 and 0.02 mg per mouse decreased the immobility time
without reaching the statistical significance. The ANOVA on the
immobility time revealed a significant group effect (F(6,77) 11.332;
p < 0.0001). Bonferroni/Dunn multiple comparison analysis
showed that the administration of either 0.05 (p < 0.05) or 0.1 mg
(p < 0.01) per mouse i.c.v. induced a statistically significantantidepressant-like effect (Fig. 2a). Similarly, the i.c.v. administra-
tion of the PKC blocker chelerytrine produced an antidepressant-
like effect (F(4,63) 56.498; p < 0.001). The dose of 1 mg per mouse
i.c.v was ineffectivewhereas the statistical significance (Bonferroni/
Dunn multiple comparison analysis) was reached at 2.5 (p < 0.01)
and 5 (p < 0.0001) mg per mouse i.c.v. (Fig. 2b).
The intensity of the calphostin C, and chelerytrine antidepres-
sant-like effect was comparable to that produced by amitriptyline
(10 mg kg1 s.c.), used as reference drug.
Co-administratrion of calphostin C (0.1 mg per mouse i.c.v.) with
the PKC activators PMA (15 nmol per mouse i.c.v.) or PDBu (40 nmol
per mouse i.c.v.) prevented the calphostin C-induced reduction of
the immobility time up to control values (Fig. 2c). Similarly, PMA
and PDBu prevented the antidepressant-like effect of chelerytrine
(5 mg per mouse i.c.v.) (Fig. 2c). PMA and PDBu, when administered
alone, were devoid of any effect on immobility time (Fig. 2c).
PKCg isoform protein knockdown induced an antidepressant-
like phenotype (F(3,52) 4.217 p < 0.01), even if of lower intensity
than that produced by pharmacological blockers of PKC. The dose of
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Fig. 3. Antidepressant-like effect produced by knockdown of PKCg following admin-
istration of a specific antisense oligonucleotide (anti-PKCg). (a) Decrease of the
immobility time in the mouse forced swimming test by anti-PKCg (1e3 nmol per
mouse i.c.v.) 24 h after the end of the aODN treatment. (b) Reversibility of the anti-
depressant-like phenotype 7 days after the end of the aODN treatment (3 nmol per
mouse i.c.v.). Amitriptyline (AMI, 10 mg kg1 i.p.) was used as reference drug; dODN:
degenerate oligonucleotide. Vertical lines represent SEM. *p < 0.05, ***p < 0.001 in
comparison with control mice. (c) Reduction of PKCg protein expression in mouse
cortex and hippocampus by aODN treament in comparison with dODN-treated mice.
Samples (10 mg protein/lane) of mouse cortex and hippocampus were resolved on 10%
SDSePAGE, transferred to nitrocellulose and probed with PKCg antibody. b-actin was
used as loading control. The columns represent the densitometric quantitation of
immuno-reactive protein expressed relative to control. Data are expressed as
mean  SEM of band intensities from each group (n ¼ 6 per group). Representative
immuno-blots were reported above each column. *p < 0.05 versus control.
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Fig. 2. Antidepressant-like effect produced by pharmacological blockade of PKC
activity. Dose-dependent decrease of the immobility time in the mouse forced
swimming test by the PKC blockers calphostin C (0.001e0.1 mg per mouse i.c.v.) (a) and
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10 mg kg1 i.p.), used as reference drug. (c) Prevention by pretreatment with the PKC
activators PMA (15 pmol per mouse i.c.v.) and PDBu (40 pmol per mouse i.c.v.) of the
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*p < 0.05, ***p < 0.001 in comparison with control mice.
N. Galeotti, C. Ghelardini / Neuropharmacology 60 (2011) 937e943940anti-PKCg of 1 nmol per mouse was ineffective; the statistical
significance was reached pre-treating animals with the dose of
3 nmol per mouse i.c.v. (Fig. 3a). Animals exposed to an FST session
7 days after the end of the aODN treatment showed the absence of
any antidepressant-like activity as indicated by the immobility time
values that were comparable to those produced by the control
group (Fig. 3b).3.3. Effect of aODN on PKCg protein levels
Mice were treated with the aODN on day 1, 2 and 3. On day 4,
24 h after the last i.c.v. injection, mice were killed and thehippocampus and frontal cortex were dissected and examined for
the levels of expression of PKCg in comparison with mice treated
with dODN. Fig. 3c shows a representative immunoblot where
a prominent approximately 80 kDa protein band was observed,
indicating that PKCg was expressed in the above-mentioned cere-
bral areas. The dODN did not significantly change the level of
immunostaining when compared with that of naive animals (data
not shown). Densitometric analysis of all samples revealed
a statistically significant reduction of the expression of PKCg after
aODN treatment in comparison with mice treated with dODN in
both cerebral areas (Fig. 3c). Levels of PKCg protein expression
returned to normal 7 days after the end of the aODN treatment
(data not shown).
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N. Galeotti, C. Ghelardini / Neuropharmacology 60 (2011) 937e943 9413.4. Effect of PLC and PKC modulators on mouse motor coordination
and locomotor behaviour
Mice pretreated with the PLC and PKC inhibitors were evaluated
for motor coordination and locomotor behaviour by use of the rota
rod and holeeboard tests, respectively.
The number of falls from the rotating rod, evaluated before and
15, 30 and 45 min after the beginning of the rota rod test, showed
the lack of any alteration in the motor coordination following
administration of the highest effective doses of the PLC inhibitors
neomycin (20 mg per mouse i.c.v.) and U73122 (5 mg per mouse
i.c.v.), the PKC inhibitors calphostin C (0.2 mg per mouse i.c.v.),
chelerytrine (5 mg per mouse i.c.v.) and the PKC activators PMA
(15 nmol per mouse i.c.v.) and PDBu (40 nmol per mouse i.c.v.), in
comparison with the corresponding control group (Fig. 4a,b).
The spontaneous mobility (Fig. 5a) and exploratory activity
(Fig. 5b) of mice treated with the highest effective doses of the
above-mentioned compounds were unmodified in comparison
with the control group. In the same experimental conditions D-
amphetamine, used as positive control, significantly increased both
spontaneous mobility and exploratory activity (Fig. 5a,b).
4. Discussion
The role of PIePKC signalling pathway in the molecular mecha-
nism of depression has increasing consensus, but data are often
controversial and still await further investigation. We, therefore,
studied the involvement of the PLCePKC pathway in a behavioural
despair paradigm, the mouse forced swimming test (FST), providing
evidence for a role of PLC and PKC in the induction of an antide-
pressant-like condition. FST is a putative animal model of depres-
sion, which emulates the behavioural despair paradigm of
depression. Currently it is one of the most frequently usedSAL
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Fig. 4. Lack of alteration of mouse motor coordination by PLC and PKC modulators. The
absence of any modification in the number of falls from the rotating rod by the PLC
inhibitors neomycin (NEOM) (a) and U73122, the PKC inhibitors calphostin C (CALPH)
and chelerytrine (CHEL), and the PKC activators PMA and PDBu (b) was observed in
comparison with corresponding control group. SAL: saline; VEH: 0.5% DMSO. Vertical
lines represent SEM.behavioural tests for investigating antidepressant potential that is
sensitive to acute drug administration, and provides a high degree of
pharmacological predictive validity (Petit-Demouliere et al., 2005).
Several PLC inhibitors are currently available. U73122, an ami-
nosteroid, has been found to be a potent inhibitor of aggregation of
human platelets induced by a variety of agonists, and this
compound has been further characterised as an inhibitor of G
protein-mediated PLC (Wakdo et al., 1983; Yule and Williams,
1992), Neomycin has been reported to inhibit hormone-stimu-
lated IP3 production through the blockade of PLC (Phillippe, 1994).
A single i.c.v. administration of the specific PLC inhibitors U73122
and neomycin produced an antidepressant-like response of inten-
sity comparable to that induced by amitriptyline, taken as antide-
pressant reference drug. An unspecific effect of the treatments can
be excluded since, U73343, a succinimido analogue used as nega-
tive control for U73122 being a weak inhibitor of PLC (Bleasdale
et al., 1990; Smith et al., 1990), did not modify the immobility
time values in comparison with the control group. These results
indicate that inhibition of the PLC activity produces an antide-
pressant-like behaviour further suggesting that the stimulation of
the PLC-mediated pathwaymight be involved in affective disorders.
On the basis of sequence homology and localisation of structural
domains PLC has been characterized into three major families: b,
d and g (Rebecchi and Pentyala, 2000; Rhee, 2001). All PLC
isozymes recognise PIP2 as a substrate and carry out Ca2þ-depen-
dent hydrolysis of inositol lipids; however these enzymes are
differentially regulated and expressed. PLCb is activated by recep-
tors that activate the Gq family of the G proteins, whereas PLCg is
regulated by receptors and non-receptor tyrosine kinases (Rhee,
2001). Little is known about the regulation of PLCd. The PLCb
family has been divided into 4 isoforms: b1, b2, b3 and b4. The PLCb1,
b3 and b4 are expressed in the brain whereas the PLCb2 has a poor
cerebral expression (Ross et al., 1989; Tanaka and Kondo, 1994).
Among the PLCb isoforms, the antisense-induced knockdown of the
PLCb1 produced an antidepressant-like phenotype in contrast to
N. Galeotti, C. Ghelardini / Neuropharmacology 60 (2011) 937e943942the inhibition of the expression of the PLCb3 isoform, which was
devoid of any effect on the immobility time. These results indicate
a prominent role of the PLCb1 isoform in the modulation of
depressive conditions and identify the inactivation of this PLC
isoform as a potential strategy for antidepressant therapy. This
hypothesis is supported by literature data indicating that antide-
pressant drugs from different classes specifically decreased PLCb1
protein levels in rat cortex and hippocampus (Dwivedi et al., 2002).
PLC isozymes hydrolyse the highly phosphorylated lipid phos-
phatidylinositol 4,5-biphosphate generating two intracellular
products: IP3, a universal calcium-mobilising second messenger,
and diacylglycerol (DAG), an activator of PKC. PKC is a family of
phosphorylating enzymes that are divided into three groups based
on calcium and DAG dependence: conventional (a, bI, bII, g), novel
(d,3,h,q), atypical (z, l/i) (Way et al., 2000). The translocation of
these enzymes from the cytosol to the synaptic membrane is
thought necessary for their activation (Nishizuka, 1992). In the
present study, pretreatment with calphostin C and chelerytrine,
selective, potent and membrane-permeable PKC inhibitors
(Kobayashi et al., 1989; Herbert et al., 1990) produced an antide-
pressant-like behaviour showed by a dose-dependent reduction of
the immobility time values in the FST. Furthermore, activation of
PKC by phorbol esters, such as PMA and PDBu (Nishizuka, 1992),
prevented the antidepressant activity produced by the PKC blockers
confirming that the antidepressant phenotype produced by cal-
phostin C and chelerytrine underlie a selective blockade of PKC.
Recently, it has been demonstrated that the PKC inhibitor tamox-
ifen reduces the amphetamine-induced hyperlocomotion, an
animal model of mania (Einat et al., 2007; Sabioni et al., 2008), and
produces an anti-manic effect in patients with bipolar disorders
(Zarate et al., 2007; Yildiz et al., 2008), supporting the possibility
that PKC signalling pathway may play an important role in the
pathophysiology and treatment of bipolar disorders. Present results
clearly indicate that blockade of the PKC-mediated pathway is
related to the induction of an antidepressant phenotype, suggesting
that PKC is not only confined to the induction/treatment of mania in
bipolar disorders. This hypothesis is also supported by the obser-
vation that repeated administration of fluoxetine and desipramine,
antidepressant drugs effective in the treatment of major depression
and dysthymia, decreased the basal activity of soluble and partic-
ulate PKC in rat cerebral cortex and hippocampus (Mann et al.,
1995) and in platelets from affective disorders subjects (Morishita
et al., 1999). The activation of PKC might, therefore, constitute
a significant pathway involved in the pathophysiology of affective
disorders and its inactivation might represent an important ther-
apeutical approach.
PKC is highly expressed in the brain and the expression is iso-
form- and region-specific, suggesting that the enzyme is involved
in selective cellular functions. Among the PKC isoform, PKCg is
solely expressed in the central nervous system, where it is partic-
ularly concentrated in the hippocampus and cortex (Saito et al.,
1988), brain regions most likely to be implicated in response to
depression. There are morphological and functional alterations in
the both brain regions in humans with major depression, such as
reduced volume of the hippocampus (Bremner, 2002), and altered
metabolism in the prefrontal cortex (Drevets et al., 1997). We, then,
decided to investigate the involvement of the PKCg isoform in
mood disorders. The inhibition of the expression of PKCg following
administration of a specific antisense oligonucleotide (aODN)
reduced the immobility time values, indicating the presence of an
antidepressant-like phenotype. On the bases of these observations,
it is plausible to suppose that an over-stimulation of the PKCg
might be present in depressed patients and that the inactivation of
PKCg may represent a new target for the antidepressant therapy.
However, a decreased catalytic activity and expression of PKCg inprefrontal cortex and hippocampus of teenage suicide victims has
been observed (Pandey et al., 2004). This discrepancy might be
explained by taking into consideration that the neurobiology of
teenagers is different from that of adults, since the observation that
responses to antidepressant treatments (Hazell et al., 1995; Emslie
et al., 1997) and risk factors for suicide (Apter et al., 1995; Brent
et al., 1993) differ between adolescents and adults with depression.
The capability of the aODN treatment to knockdown PKCg was
demonstrated by immuno-blotting experiments where a selective
decrease of PKCg protein levels was detected in the hippocampus
and frontal cortex. These results showed that the antidepressant
phenotypic effect was related to a selective knockdown of the PKCg
isoform. The degenerate ODN (dODN), used as control for the
unspecific effects attributable to the administration of nucleic acids
irrespective of their specific sequence, did not modify the immo-
bility time in comparison with naive or vector-injected mice. This
observation ruled out the possibility that the antidepressant
behaviour showed by PKCg knockdown animals may have resulted
from a sequence-independent action on cerebral structures. The
antidepressant-like effect induced by anti-PKCg disappeared 7 days
after the end of the antisense administration, indicating an absence
of irreversible damage or toxicity on cerebral structures caused by
the aODNs.
The FST is widely used to predict the antidepressant action of
drugs in humans. However, this animal model has also some
drawbacks represented by the possibility to obtain some false
positives or negatives by drugs that modify motor activity, which,
therefore, may alter the immobility time values recorded. The
reduced immobility time observed following injection of PLC and
PKC modulators was not accompanied by any modification of
spontaneous mobility and locomotor activity of mice, potential
confounds for the evaluation of a depressant/antidepressant effect.
Present results demonstrate that acute pharmacological
blockade of PLCb1ePKCg signalling pathway produces an antide-
pressant-like phenotype in the mouse FST. These findings suggest
the PLCePKC cascade as critical target underlying depressive states
and should facilitate the comprehension of the etiopathology of
mood disorders and help developing new therapeutical strategies.
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